Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus-Based GVHD Prophylaxis in ALL HSCT
NCT00382109Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Mar 2007
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of sirolimus in graft-versus-host disease (GVHD) (2 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-Free Survival at 2 years. Started Mar 2007; status: completed.
02
Drugs
sirolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00382109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382109.